A Remote Chronic Disease Management Program to Improve Cardiovascular and Metabolic Outcomes in a Diverse Community-Based Diabetic Population: Study Design of the TAMIS Trial
Abstract
Introduction: Cardiovascular and cerebrovascular diseases are projected to expand in the coming decades as the main cause of death. This study outlines the escalating burden of cardiovascular diseases in low- and middle-income countries (LMICs), particularly in Latin America (LA), which is expected to surpass that of other high-population regions. Despite advances in prevention strategies, adherence to therapeutic goals remains a global challenge, especially in LMICs where control rates are notably low for conditions such as hypertension, type 2 diabetes mellitus (DM2), and dyslipidemia. Emerging evidence from LMICs supports the feasibility and effectiveness of telehealth interventions for cardiometabolic disease management in primary care.
Aims: To address these challenges, a remote chronic disease management program has been developed to optimize risk factor control through standardized medical protocols and task automation.
Methods: This is an open-label randomized and decentralized clinical trial describing the design and methodology of the TAMIS program, which will assess its impact on community-dwelling diabetic subjects with uncontrolled HBA1c and uncontrolled LDL-C and/or blood pressure. Individuals will be randomized to usual care or remote care and followed for 84 weeks. Remote monitoring offers a practical response to the limited capacity of LMIC health systems to ensure sustained follow-up and continuity of care for chronic conditions. The primary endpoint is a…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.